Frontier Ip Regulatory News (FIPP)

The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310 ("MAR"). With the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

RNS

AIM: FIPP

28 April 2021

Frontier IP Group plc

("Frontier IP" or the "Group")

Portfolio news - Exscientia announces investment of up to $525 million led by SoftBank Vision Fund 2

Frontier IP, a specialist in commercialising intellectual property, notes the following statement from portfolio company Exscientia Limited ("Exscientia" or the "Company") announcing an investment of up to $525 million.

The Company has closed a Series D funding round of $225 million and can access a further $300 million from SoftBank at its discretion.

Exscientia statement begins:

Exscientia announces investment of up to $525M

Exscientia announces investment of up to $525M

Proceeds to continue expansion of proprietary pipeline and end-to-end AI drug discovery capabilities

$225 million Series D round closed with access up to an additional $300 million at Exscientia's discretion

Financing led by SoftBank Vision Fund 2

Exscientia, a clinical stage pharmatech company using artificial intelligence (AI) to design patient-based drugs, announced that it has completed a $225 million Series D funding round. SoftBank Vision Fund 2i led the Series D and was joined by previous round lead investors, Novo Holdings and funds managed by Blackrock. Other investors included Mubadala Investment Company, Farallon Capital, Casdin Capital, GT Healthcare Capital, Marshall Wace, Pivotal bioVenture Partners, Laurion Capital, Hongkou and Bristol-Myers Squibb. In addition, SoftBank is providing an additional $300 million equity commitment that can be drawn at the Company's discretion.

Exscientia uses AI across its platform from target identification through drug design and patient selection in order to precision engineer new medicines. The Company has advanced the first two fully AI-designed drugs into clinical trials and now has over 20 active programs in its pipeline. Funding from the Series D round will be used to advance Exscientia's proprietary pipeline through clinical testing as well as to continue expanding the technology platform toward autonomous drug design.

Commenting on the investment, Eric Chen, Managing Partner of SoftBank Investment Advisers, said: "We believe Exscientia's innovative use of AI to discover and design better quality drugs with greater efficiency has the potential to create important medicines faster than ever before. With the convergence of technology and biology, drug discovery is rapidly evolving in ways that will reshape the industry. The Exscientia team have been leaders in AI-based drug discovery since the field's inception and we believe they will continue shaping its future."

Exscientia has built and integrated a broad array of AI and experimental technologies to capture and utilize the most patient-relevant data to precision design drugs for multiparameter optimization. The Company's platform evaluates the target and mechanism through high content phenomics, novel biophysics and deep learning from biological data. That information is then translated into the design of precision drugs through proprietary AI algorithms driven by thousands of models. By remaking the process of drug discovery, Exscientia is also able to reset industry standards for productivity. To date, the Company has been able to advance seven precision designed drugs from project initiation to development candidate in an average time of 12 months.

Andrew Hopkins, CEO of Exscientia added, "All of our investors share Exscientia's vision to discover better drugs, faster, through AI and automation. Our patient-first AI platform has repeatedly demonstrated its ability to precision design drugs that address patients' needs. With the Series D completed, the quality and depth of our shareholder base allows us the freedom to continue to scale both our platform and pipeline."

iAs of the date of this press release, SoftBank Group Corp. has made capital contributions to allow investments by SoftBank Vision Fund 2 ("SVF 2") in certain portfolio companies. The information included herein is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy limited partnership interests in any fund, including SVF 2. SVF 2 has yet to have an external close, and any potential third-party investors shall receive additional information related to any SVF 2 investments prior to closing.

Exscientia statement ends

ENQUIRIES

ABoUT EXscientia

Exscientia is an AI-driven pharmatech company committed to discovering and designing the best possible medicines in the fastest and most effective manner. Exscientia is the first company to progress AI-designed small molecules into the clinical setting and repeatedly demonstrate the ability of AI to transform how drugs are created. Exscientia's AI platform has now designed two drugs that are in Phase 1 human clinical trials.

Drug design is precision engineering at the molecular scale. Exscientia has built dedicated AI systems that efficiently learn from the widest range of data and consistently reapply enhanced knowledge through iterations of design. Because Exscientia's AI platform learns more effectively and rapidly than human-led efforts alone, candidate molecules satisfying complex therapeutic requirements are created with revolutionary efficiency. Exscientia believes that designing better drugs, faster, will allow the best ideas of science to rapidly become the best medicines for patients.

Exscientia has offices in Oxford, Miami, Osaka and Dundee. For more information visit www.exscientia.ai or follow Exscientia on Twitter @exscientiaAI.

ABOUT FRONTIER IP

Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services. A critical part of the Group's work is involving relevant industry partners at an early stage of development to ensure technology meets real world demands and needs.

The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.